ClinicalTrials.gg
CompletedNCT02476006Updated Mar 28, 2022Results posted

Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE)

A Phase 3 interventional study of ALIROCUMAB SAR236553 (REGN727) and placebo (for injection training only) in Hypercholesterolemia, sponsored by Sanofi. Completed at 153 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-28.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
998
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 43 studies testing alirocumab in Hypercholesterolemia — 1 open to participants now, 2 under way, none of them phase 3. alirocumab · Hypercholesterolemia.

Enrollment
4th of 43
998 · median 107
Started
2015
with 2 others
Phase 3
20 of 43
none open now
Registered
28th of 43
by date
Lead sponsor
28 of 43
Sanofi

Among the 43 studies testing alirocumab in Hypercholesterolemia, this one is the 4th largest by enrollment, is one of 3 that started in 2015, is one of 20 in phase 3, and was the 28th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

1 of the 43 studies testing alirocumab in Hypercholesterolemia is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About alirocumab

alirocumab: first FDA approval 2015 (PRALUENT), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing alirocumab in Hypercholesterolemia, or all of them as a file.
02

Study summary

Primary Objective:

To provide participants with severe hypercholesterolemia at risk for subsequent cardiovascular (CV) events and not adequately controlled with currently available lipid-modifying therapy (LMT) access to alirocumab ahead of commercial availability and to document the overall safety and tolerability of alirocumab in this participant population.

Secondary Objectives:

To document the effect of alirocumab on low-density lipoprotein cholesterol (LDL-C) levels as well as non-high-density lipoprotein cholesterol (non-HDL-C), total cholesterol (total-C), high-density lipoprotein cholesterol (HDL-C), and triglyceride (TG) levels after 12 weeks of treatment.

To document participant's acceptability of self-injection (Self Injection Assessment Questionnaire, SIAQ).

Read the detailed description

The study duration included a screening period of up to 3 weeks, a treatment period of a minimum of 12 weeks and up to a maximum of 120 weeks (30 months), and at least 2 weeks after the last study treatment injection.

03

Conditions studied

  • Hypercholesterolemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Either A, B, C, D, or E below and not adequately controlled with a maximally tolerated dose of statin with or without other LMTs, all at stable doses for at least 4 weeks prior to the screening visit (Week-3):

A. Participants suffering from heterozygous familial hypercholesterolemia (heFH) with LDL-C concentrations greater than or equal to (>=)160 mg/dL (4.14 millimoles per liter [mmol/L]) despite treatment.

B. Participants suffering from heFH with LDL-C concentrations >=130 mg/dL (3.36 mmol/L) despite treatment and two or more CV risk factors among this list:

  • LDL-C greater than (>) 250 milligrams per deciliter (mg/dL) (6.46 mmol/L) at the time of the familial hypercholesterolemia (FH) diagnosis (before treatment).
  • Family history of premature-onset coronary heart disease (CHD; first-degree male relative with onset before age 55 years; first-degree female relative with onset before age 65 years).
  • Metabolic syndrome.
  • HDL-C less than (\<) 40 mg/dL (1.03 mmol/L).
  • Hypertension (blood pressure >140/90 mmHg or drug treatment).
  • Lipoprotein a (Lp[a]) >=50 mg/dL (1.78 µmol/L).
  • Tendon xanthoma.

C. Participants suffering from heFH with LDL-C concentrations >=130 mg/dL (3.36 mmol/L) despite treatment and one of the following characteristics:

  • Established CHD or other cardiovascular disease (CVD; history of acute myocardial infarction, ischemic stroke, peripheral arterial disease, coronary or peripheral arterial revascularization, stable or unstable angina, , carotid artery stenosis >=50 percent (%), or aortic abdominal aneurysm).
  • Drug-treated type 2 diabetes mellitus or type 1 with target organ damage.
  • Family history of first- or second-degree relative with very premature onset CHD (first- or second-degree male relative with onset before age 45; first- or second-degree female relative with onset before age 55).

D. Non-FH participants suffering from established CHD or other CVD (history of acute myocardial infarction (MI), ischemic stroke, peripheral arterial disease, coronary or peripheral arterial revascularization, stable or unstable angina, transient ischemic attack, carotid artery stenosis >=50%, or aortic abdominal aneurysm) and with LDL-C concentrations >=130 mg/dL (3.36 mmol/L).

E. Participants suffering from progressive CVD (coronary artery disease, or peripheral arterial occlusive disease or cerebrovascular disease as documented clinically or by imaging techniques, with a subsequent CV event [acute MI, ischemic stroke, ischemia-driven revascularization, unstable angina, transient ischemic attack] occurring despite stable doses of maximally tolerated LMT) with LDL-C concentrations >=100 mg/dL (2.59 mmol/L).

Exclusion criteria

Exclusion criteria:

Not on a stable dose of LMT (including statin) for at least 4 weeks prior to the screening visit (Week -3) and from screening to enrollment.

Use of a fibrate other than fenofibrate within 4 weeks of the screening visit (Week-3) or between screening and enrollment.

Daily doses above atorvastatin 80 mg, rosuvastatin 40 mg, or simvastatin 40 mg (except for participants on simvastatin 80 mg for more than one year, who were eligible).

Use of statin other than simvastatin, atorvastatin, or rosuvastatin prior to the screening visit (Week-3) or between screening and enrollment, except when there was a documented reason for intolerance to the above mentioned potent statins (in which case the use of a different statin was allowed).

Fasting serum TG >400 mg/dL (>4.52 mmol/L) at the screening visit (Week -3). Uncontrolled hypertension (>180 mmHg systolic and/or >110 mmHg diastolic at randomization visit).

Class III or IV congestive heart failure persisting despite treatment.

History of hemorrhagic stroke. Liver transaminases >3 times the . Laboratory evidence of current or C infection. Creatine kinase >3 times the upper limit of normal. Estimated \<30 mL/min/1.73 m\^2. Pregnant or breastfeeding woman or with without appropriate .

Male participant with a female partner of childbearing potential not protected by a highly-effective method(s) of birth control.

Participants eligible for enrollment into an ongoing clinical study of alirocumab conducted at the same site.

to alirocumab or any of the .

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
998 participants (actual)

Study arms

  • Experimental
    Alirocumab

    Participants received Alirocumab 150 milligram (mg) subcutaneously (SC) once every two weeks (Q2W) or 75 mg SC Q2W added to stable LMT up to a maximum of 120 weeks. Alirocumab dose was either up-titrated from 75 to 150 mg Q2W or down-titrated from 150 to 75 mg Q2W, based on Investigator judgment and treatment response.

    Drug: ALIROCUMAB SAR236553 (REGN727) · Drug: placebo (for injection training only) · Drug: ezetimibe · Drug: atorvastatin · Drug: rosuvastatin · Drug: simvastatin

Interventions

  • Pharmaceutical form:solution Route of administration: subcutaneous

    Also known as: Praluent®

  • Drugplacebo (for injection training only)

    Pharmaceutical form:solution Route of administration: subcutaneous

  • Pharmaceutical form:capsule Route of administration: oral

  • Pharmaceutical form:tablet Route of administration: oral

  • Pharmaceutical form:tablet Route of administration: oral

  • Pharmaceutical form:tablet Route of administration: oral

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Treatment Emergent Adverse Events (TEAEs)

    Adverse Event (AE) was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. Treatment-emergent AEs (TEAEs) were defined as AEs that that developed or worsened or became serious during the TEAE period (time from the first injection of study drug up to the day of the last injection of study drug + 14 days). A Serious Adverse Event (SAE) was any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event.

    Time frame: From first injection of investigational medicinal product (IMP) up to 2 weeks after last dose of study drug (Week 120)

Secondary outcomes

  1. Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol (LDL-C) at Week 12

    Calculated LDL-C values were obtained using the Friedewald formula. Calculated LDL-C in mg/dL from Friedewald formula (LDL cholesterol = Total cholesterol - HDL cholesterol - \[Triglyceride/5\]). Baseline value was defined as the last observation before the first dose of the treatment.

    Time frame: Baseline, Week 12

  2. Percentage of Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 12

    LDL-Cholesterol was calculated using the Friedewald formula. Percentage of participants who reached calculated LDL-C \<100 mg/dL (2.59 mmol/L) at week 12 were reported.

    Time frame: At Week 12

  3. Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 12

    LDL-Cholesterol was calculated using the Friedewald formula. Percentage of participants who reached calculated LDL-C \<70 mg/dL (1.81 mmol/L) at week 12 were reported.

    Time frame: At Week 12

  4. Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) and/or >=50% Reduction From Baseline in LDL-C at Week 12

    LDL-Cholesterol was calculated using the Friedewald formula. Percentage of participants who reached LDL-C \<70 mg/dL at Week 12 and/or \>=50% reduction from baseline in LDL-C at Week 12 are reported.

    Time frame: At Week 12

  5. Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 12

    Baseline value was defined as the last observation before the first dose of the treatment.

    Time frame: Baseline, Week 12

  6. Percent Change From Baseline in Total Cholesterol (Total-C) at Week 12

    Baseline value was defined as the last observation before the first dose of the treatment.

    Time frame: Baseline, Week 12

  7. Percent Change From Baseline in High Density Lipoprotein Cholesterol at Week 12

    Baseline value was defined as the last observation before the first dose of the treatment.

    Time frame: Baseline, Week 12

  8. Percent Change From Baseline in Triglycerides at Week 12

    Baseline value was defined as the last observation before the first dose of the treatment.

    Time frame: Baseline, Week 12

  9. Assessment of Participant's Acceptability of Self-Injection Using Self Injection Assessment Questionnaire (SIAQ): Feeling About Injections, Self Confidence, Satisfaction With Self-Injections

    Pre-SIAQ: self-completed before first self-injection \& Post-SIAQ: self-completed after self-injection. Pre-SIAQ consisted of 7 items grouped into 3 domains:feelings about injections,self-confidence \& satisfaction with self-injection. Post-SIAQ consisted of 21 items grouped into 6 domains:feelings about injections,self-image,self-confidence,injection-site reactions,ease of use \& satisfaction with self-injection. Participants rated each item on 5-point (or 6-point) semantic Likert-type scale, where lower numbers indicate a worse experience. Item scores were transformed to obtain a score ranging from 0 (worst experience) to 10 (best experience). Transformed scores for items contributing to a domain were then averaged into a domain score. Each domain score ranges from 0 (worst experience) to 10 (best experience), higher score=better acceptability. Domain scores common to the Pre \& Post SIAQ were analyzed on participants belonging to Pre \& Post-SIAQ population and are reported.

    Time frame: Baseline (Pre-SIAQ), Week 4, Week 8, Week 12, Week 24, Week 48, Week 72, Week 96

  10. Assessment of Participant's Acceptability of Self-Injection Using Self Injection Assessment Questionnaire (SIAQ): Self Image, Injection-Site Reactions, Ease of Use

    SIAQ: contained 2 modules: Pre-SIAQ and Post-SIAQ. Post-SIAQ: self-completed after self-injection. Post-SIAQ consisted of 21 items grouped into 6 domains: feelings about injections, self-image, self-confidence, injection-site reactions, ease of use \& satisfaction with self-injection. Participants rated each item on 5-point (or 6-point) semantic Likert-type scale, where lower numbers indicated a worse experience. Item scores were transformed to obtain a score ranging from 0 (worst experience) to 10 (best experience) for each item. Transformed scores for items contributing to a domain were then averaged into a domain score. Each domain score ranges from 0 (worst experience) to 10 (best experience), higher score=better acceptability. Domain scores which are not in common with Pre-SIAQ were analyzed on the Post-SIAQ population and are reported here.

    Time frame: Week 4, Week 8, Week 12, Week 24, Week 48, Week 72, Week 96

07

Results

Posted Mar 30, 2020

Participant flow

The study was conducted at 156 sites in 17 countries. A total of 1305 participants were screened between 23-June-2015 to 27-December 2016, of whom 307 were screen failures. Screen failures were mainly due to exclusion criteria met.

Participant flow — Overall Study
MilestoneAlirocumab
Started998
Treated994
Completed878
Not completed120
Withdrew: Death4
Withdrew: Lack of treatment efficacy2
Withdrew: Pregnancy1
Withdrew: Participant did not wish to continue39
Withdrew: Adverse event41
Withdrew: Poor compliance to study protocol3
Withdrew: Sponsor decision6
Withdrew: Lost to follow-up5
Withdrew: Physician decision5
Withdrew: Study ended treatment not available4
Withdrew: Switched to commercial drug4
Withdrew: Excluded from study1
Withdrew: Protocol violation1
Withdrew: Enrolled but not treated4

Outcome measures

PrimaryPercentage of Participants With Treatment Emergent Adverse Events (TEAEs)

Adverse Event (AE) was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. Treatment-emergent AEs (TEAEs) were defined as AEs that that developed or worsened or became serious during the TEAE period (time from the first injection of study drug up to the day of the last injection of study drug + 14 days). A Serious Adverse Event (SAE) was any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event.

Time frame:
From first injection of investigational medicinal product (IMP) up to 2 weeks after last dose of study drug (Week 120)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment Emergent Adverse Events (TEAEs)
percentage of participantsAlirocumab
Any TEAE71.6
Any treatment emergent SAE16.2
Any TEAE leading to death0.2
Any TEAE leading to treatment discontinuation4.5
SecondaryPercent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol (LDL-C) at Week 12

Calculated LDL-C values were obtained using the Friedewald formula. Calculated LDL-C in mg/dL from Friedewald formula (LDL cholesterol = Total cholesterol - HDL cholesterol - \[Triglyceride/5\]). Baseline value was defined as the last observation before the first dose of the treatment.

Time frame:
Baseline, Week 12
Reported as:
Mean · percent change
Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol (LDL-C) at Week 12
percent changeAlirocumab
Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol (LDL-C) at Week 12-54.84 ± 20.06
SecondaryPercentage of Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 12

LDL-Cholesterol was calculated using the Friedewald formula. Percentage of participants who reached calculated LDL-C \<100 mg/dL (2.59 mmol/L) at week 12 were reported.

Time frame:
At Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 12
percentage of participantsAlirocumab
Percentage of Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 1274.6 (71.7 to 77.4)
SecondaryPercentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 12

LDL-Cholesterol was calculated using the Friedewald formula. Percentage of participants who reached calculated LDL-C \<70 mg/dL (1.81 mmol/L) at week 12 were reported.

Time frame:
At Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 12
percentage of participantsAlirocumab
Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 1250.2 (46.9 to 53.4)
SecondaryPercentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) and/or >=50% Reduction From Baseline in LDL-C at Week 12

LDL-Cholesterol was calculated using the Friedewald formula. Percentage of participants who reached LDL-C \<70 mg/dL at Week 12 and/or \>=50% reduction from baseline in LDL-C at Week 12 are reported.

Time frame:
At Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) and/or >=50% Reduction From Baseline in LDL-C at Week 12
percentage of participantsAlirocumab
Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) and/or >=50% Reduction From Baseline in LDL-C at Week 1269.1 (66.0 to 72.0)
SecondaryPercent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 12

Baseline value was defined as the last observation before the first dose of the treatment.

Time frame:
Baseline, Week 12
Reported as:
Mean · percent change
Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 12
percent changeAlirocumab
Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 12-45.89 ± 35.82
SecondaryPercent Change From Baseline in Total Cholesterol (Total-C) at Week 12

Baseline value was defined as the last observation before the first dose of the treatment.

Time frame:
Baseline, Week 12
Reported as:
Mean · percent change
Percent Change From Baseline in Total Cholesterol (Total-C) at Week 12
percent changeAlirocumab
Percent Change From Baseline in Total Cholesterol (Total-C) at Week 12-38.28 ± 15.20
SecondaryPercent Change From Baseline in High Density Lipoprotein Cholesterol at Week 12

Baseline value was defined as the last observation before the first dose of the treatment.

Time frame:
Baseline, Week 12
Reported as:
Mean · percent change
Percent Change From Baseline in High Density Lipoprotein Cholesterol at Week 12
percent changeAlirocumab
Percent Change From Baseline in High Density Lipoprotein Cholesterol at Week 124.37 ± 17.29
SecondaryPercent Change From Baseline in Triglycerides at Week 12

Baseline value was defined as the last observation before the first dose of the treatment.

Time frame:
Baseline, Week 12
Reported as:
Mean · percent change
Percent Change From Baseline in Triglycerides at Week 12
percent changeAlirocumab
Percent Change From Baseline in Triglycerides at Week 12-8.28 ± 33.99
SecondaryAssessment of Participant's Acceptability of Self-Injection Using Self Injection Assessment Questionnaire (SIAQ): Feeling About Injections, Self Confidence, Satisfaction With Self-Injections

Pre-SIAQ: self-completed before first self-injection \& Post-SIAQ: self-completed after self-injection. Pre-SIAQ consisted of 7 items grouped into 3 domains:feelings about injections,self-confidence \& satisfaction with self-injection. Post-SIAQ consisted of 21 items grouped into 6 domains:feelings about injections,self-image,self-confidence,injection-site reactions,ease of use \& satisfaction with self-injection. Participants rated each item on 5-point (or 6-point) semantic Likert-type scale, where lower numbers indicate a worse experience. Item scores were transformed to obtain a score ranging from 0 (worst experience) to 10 (best experience). Transformed scores for items contributing to a domain were then averaged into a domain score. Each domain score ranges from 0 (worst experience) to 10 (best experience), higher score=better acceptability. Domain scores common to the Pre \& Post SIAQ were analyzed on participants belonging to Pre \& Post-SIAQ population and are reported.

Time frame:
Baseline (Pre-SIAQ), Week 4, Week 8, Week 12, Week 24, Week 48, Week 72, Week 96
Reported as:
Mean · units on a scale
Assessment of Participant's Acceptability of Self-Injection Using Self Injection Assessment Questionnaire (SIAQ): Feeling About Injections, Self Confidence, Satisfaction With Self-Injections
units on a scaleAlirocumab
Feelings about injections: Baseline8.6 ± 1.8
Feeling about injections: Week 49.1 ± 1.4
Feeling about injections: Week 89.1 ± 1.4
Feeling about injections: Week 129.2 ± 1.4
Feeling about injections: Week 249.2 ± 1.4
Feeling about injections: Week 489.2 ± 1.4
Feeling about injections: Week 729.2 ± 1.4
Feeling about injections: Week 969.3 ± 1.3
Self confidence: Baseline6.9 ± 2.4
Self Confidence: Week 48.0 ± 2.1
Self Confidence: Week 88.1 ± 2.0
Self Confidence: Week 128.1 ± 1.9
Self Confidence: Week 248.0 ± 2.1
Self Confidence: Week 488.1 ± 2.1
Self Confidence: Week 728.3 ± 2.0
Self Confidence: Week 968.4 ± 2.0
Satisfaction with self injection: Baseline7.2 ± 2.5
Satisfaction with self-injections: Week 48.5 ± 1.6
Satisfaction with self-injections: Week 88.7 ± 1.6
Satisfaction with self-injections: Week 128.7 ± 1.6
Satisfaction with self-injections: Week 248.6 ± 1.8
Satisfaction with self-injections: Week 488.7 ± 1.5
Satisfaction with self-injections: Week 728.8 ± 1.7
Satisfaction with self-injections: Week 968.8 ± 1.4
SecondaryAssessment of Participant's Acceptability of Self-Injection Using Self Injection Assessment Questionnaire (SIAQ): Self Image, Injection-Site Reactions, Ease of Use

SIAQ: contained 2 modules: Pre-SIAQ and Post-SIAQ. Post-SIAQ: self-completed after self-injection. Post-SIAQ consisted of 21 items grouped into 6 domains: feelings about injections, self-image, self-confidence, injection-site reactions, ease of use \& satisfaction with self-injection. Participants rated each item on 5-point (or 6-point) semantic Likert-type scale, where lower numbers indicated a worse experience. Item scores were transformed to obtain a score ranging from 0 (worst experience) to 10 (best experience) for each item. Transformed scores for items contributing to a domain were then averaged into a domain score. Each domain score ranges from 0 (worst experience) to 10 (best experience), higher score=better acceptability. Domain scores which are not in common with Pre-SIAQ were analyzed on the Post-SIAQ population and are reported here.

Time frame:
Week 4, Week 8, Week 12, Week 24, Week 48, Week 72, Week 96
Reported as:
Mean · units on a scale
Assessment of Participant's Acceptability of Self-Injection Using Self Injection Assessment Questionnaire (SIAQ): Self Image, Injection-Site Reactions, Ease of Use
units on a scaleAlirocumab
Self Image: Week 49.4 ± 1.4
Self Image: Week 89.4 ± 1.4
Self Image: Week 129.4 ± 1.4
Self Image: Week 249.3 ± 1.5
Self Image: Week 489.4 ± 1.4
Self Image: Week 729.3 ± 1.5
Self Image: Week 969.4 ± 1.4
Injection-site reactions: Week 49.6 ± 0.7
Injection-site reactions: Week 89.6 ± 0.8
Injection-site reactions: Week 129.6 ± 0.7
Injection-site reactions: Week 249.5 ± 0.9
Injection-site reactions: Week 489.5 ± 0.8
Injection-site reactions: Week 729.5 ± 0.8
Injection-site reactions: Week 969.5 ± 0.8
Ease of use: Week 48.7 ± 1.5
Ease of use: Week 88.7 ± 1.6
Ease of use: Week 128.8 ± 1.6
Ease of use: Week 248.8 ± 1.6
Ease of use: Week 488.9 ± 1.4
Ease of use: Week 729.0 ± 1.5
Ease of use: Week 969.0 ± 1.4

Adverse events

Collected over All AEs were collected from first injection of IMP up to 2 weeks after last dose of study drug (Week 120).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Alirocumab2/994 (0.2%)161/994 (16.2%)221/994 (22.2%)
Most frequent serious events
Showing 10 of 132
Most frequent serious events
EventAlirocumab
Angina PectorisCardiac disorders15/994
Angina UnstableCardiac disorders12/994
Coronary Artery DiseaseCardiac disorders6/994
Coronary Artery StenosisCardiac disorders6/994
Acute Coronary SyndromeCardiac disorders5/994
Acute Myocardial InfarctionCardiac disorders5/994
Atrial FibrillationCardiac disorders5/994
Myocardial IschaemiaCardiac disorders5/994
Vascular Stent StenosisGeneral disorders4/994
Cardiac FailureCardiac disorders3/994
Most frequent other events
Most frequent other events
EventAlirocumab
NasopharyngitisInfections and infestations78/994
MyalgiaMusculoskeletal and connective tissue disorders71/994
HeadacheNervous system disorders61/994
InfluenzaInfections and infestations53/994

Baseline characteristics

Analysis was performed on safety population that included all participants who had signed the informed consent form (ICF) and who had received at least one dose or partial dose of alirocumab.

Age, Continuous
Age, Continuous(years)Alirocumab
Mean56.6 ± 11.7
Sex: Female, Male
Sex: Female, Male(Participants)Alirocumab
Female369
Male625
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Alirocumab
White/Caucasian969
Black10
Asian/Oriental6
Multiracial1
Other8
08

Study locations

153 sites
  • Investigational Site Number 040001
    Graz, Austria
  • Investigational Site Number 040008
    Innsbruck, 6020, Austria
  • Investigational Site Number 040005
    Linz, 4010, Austria
  • Investigational Site Number 040006
    Linz, 4021, Austria
  • Investigational Site Number 040003
    Wien, 1030, Austria
  • Investigational Site Number 040002
    Wien, 1090, Austria
  • Investigational Site Number 040004
    Wien, 1130, Austria
  • Investigational Site Number 040007
    Wien, 1160, Austria
  • Investigational Site Number 040010
    Wien, 1160, Austria
  • Investigational Site Number 056005
    Aalst, 9300, Belgium
  • Investigational Site Number 056018
    Antwerpen, 2020, Belgium
  • Investigational Site Number 056008
    Arlon, 6700, Belgium
  • Investigational Site Number 056013
    Brugge, 8000, Belgium
  • Investigational Site Number 056010
    Brussel, 1090, Belgium
  • Investigational Site Number 056003
    Bruxelles, 1200, Belgium
  • Investigational Site Number 056006
    Charleroi, 6000, Belgium
  • Investigational Site Number 056007
    Edegem, 2650, Belgium
  • Investigational Site Number 056019
    Genk, 3600, Belgium
  • Investigational Site Number 056001
    Gent, 9000, Belgium
  • Investigational Site Number 056017
    Gent, 9000, Belgium
  • Investigational Site Number 056002
    Haine St Paul, 7100, Belgium
  • Investigational Site Number 056015
    Kortrijk, 8500, Belgium
  • Investigational Site Number 056009
    La Louvière, 7100, Belgium
  • Investigational Site Number 056004
    Leuven, 3000, Belgium
  • Investigational Site Number 056014
    Liège, 4000, Belgium
  • Investigational Site Number 056011
    Overpelt, 3900, Belgium
  • Investigational Site Number 056016
    Roeselare, 8800, Belgium
  • Investigational Site Number 124018
    Calgary, T2E7C5, Canada
  • Investigational Site Number 124015
    Cambridge, N1R6V6, Canada
  • Investigational Site Number 124002
    Chicoutimi, G7H7K9, Canada
  • Investigational Site Number 124027
    Coquitlam, V3K3P4, Canada
  • Investigational Site Number 124025
    Edmonton, T6G2B7, Canada
  • Investigational Site Number 124017
    Halifax, B3H1V7, Canada
  • Investigational Site Number 124013
    Hamilton, L8L 2X2, Canada
  • Investigational Site Number 124008
    London, N6A 4L6, Canada
  • Investigational Site Number 124026
    Maple Ridge, V2X5Z6, Canada
  • Investigational Site Number 124020
    Montreal, H2W1R7, Canada
  • Investigational Site Number 124022
    Montreal, H4A3J1, Canada
  • Investigational Site Number 124032
    Mount Pearl, A1N1W7, Canada
  • Investigational Site Number 124005
    Ottawa, K1Y4W7, Canada
  • Investigational Site Number 124024
    Peterborough, K9J0B2, Canada
  • Investigational Site Number 124003
    Quebec, G1V4W2, Canada
  • Investigational Site Number 124007
    Sarnia, N7T 4X3, Canada
  • Investigational Site Number 124001
    Sherbrooke, J1H 5N4, Canada
  • Investigational Site Number 124030
    Smiths Falls, K7A4W8, Canada
  • Investigational Site Number 124019
    St-Charles Borromee, J6E6J2, Canada
  • Investigational Site Number 124023
    Toronto, M4N3M5, Canada
  • Investigational Site Number 124014
    Toronto, M5B1W8, Canada
  • Investigational Site Number 124028
    Trois-Rivieres, Canada
  • Investigational Site Number 124011
    Vancouver, V5Y3W2, Canada
  • Investigational Site Number 124012
    Victoria, V8T5G4, Canada
  • Investigational Site Number 124031
    Winnipeg, R2H2A6, Canada
  • Investigational Site Number 124009
    Woodstock, N4S5P5, Canada
  • Investigational Site Number 203004
    Brno, 65691, Czechia
  • Investigational Site Number 203002
    Hradec Kralove, 50005, Czechia
  • Investigational Site Number 203001
    Praha, 12808, Czechia
  • Investigational Site Number 203005
    Uherske Hradiste, 68601, Czechia
  • Investigational Site Number 208001
    Esbjerg, 6700, Denmark
  • Investigational Site Number 208002
    Roskilde, 4000, Denmark
  • Investigational Site Number 208003
    Ålborg, 9000, Denmark
  • Investigational Site Number 246003
    Turku, 20520, Finland
  • Investigational Site Number 246001
    Varkaus, 78300, Finland
  • Investigational Site Number 250027
    Amiens Cedex 1, 80054, France
  • Investigational Site Number 250034
    Auxerre, 89011, France
  • Investigational Site Number 250016
    Avignon, 84000, France
  • Investigational Site Number 250021
    Bayonne, 64100, France
  • Investigational Site Number 250030
    Bobigny, 93009, France
  • Investigational Site Number 250045
    BORDEAUX Cedex, 33075, France
  • Investigational Site Number 250049
    Brest Cedex, 29610, France
  • Investigational Site Number 250054
    Bron, 69677, France
  • Investigational Site Number 250015
    Caen, 14000, France
  • Investigational Site Number 250047
    Clermont Ferrand, 63003, France
  • Investigational Site Number 250013
    Corbeil Essonnes, 91100, France
  • Investigational Site Number 250032
    Coudray, 28630, France
  • Investigational Site Number 250002
    Dijon, 21000, France
  • Investigational Site Number 250040
    Dijon, 21000, France
  • Investigational Site Number 250038
    GRENOBLE cedex, 38043, France
  • Investigational Site Number 250012
    Grenoble, 38028, France
  • Investigational Site Number 250033
    Jossigny, France
  • Investigational Site Number 250035
    LE CHESNAY Cedex, 78157, France
  • Investigational Site Number 250036
    Lens, France
  • Investigational Site Number 250042
    Lille, 59000, France
  • Investigational Site Number 250004
    Lille, France
  • Investigational Site Number 250037
    Limoges Cedex, 87000, France
  • Investigational Site Number 250057
    Lyon, 69009, France
  • Investigational Site Number 250048
    Marseille Cedex 05, 13385, France
  • Investigational Site Number 250028
    Marseille, 13385, France
  • Investigational Site Number 250024
    Montpellier, 34295, France
  • Investigational Site Number 250006
    Nantes cedex 01, 44093, France
  • Investigational Site Number 250022
    Nantes, 44277, France
  • Investigational Site Number 250017
    Nice cedex 1, 06001, France
  • Investigational Site Number 250039
    NIMES Cedex 9, 30029, France
  • Investigational Site Number 250044
    PARIS Cedex 04, 75181, France
  • Investigational Site Number 250001
    Paris Cedex 10, 75475, France
  • Investigational Site Number 250014
    Paris, 75014, France
  • Investigational Site Number 250041
    Paris, 75014, France
  • Investigational Site Number 250026
    Paris, 75018, France
  • Investigational Site Number 250051
    Pessac, 33604, France
  • Investigational Site Number 250011
    POITIERS Cedex, 86021, France
  • Investigational Site Number 250031
    Poitiers, 86021, France

Showing the first 100 of 153 sites across 16 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Cefalu AB, Garbelotto R, Mombelli G, Pirro M, Rubba P, Arca M, Borghi C, Bonomo K, Gonnelli S, Massaroni K, Tirone G, Averna M; ODYSSEY APPRISE Study Italian Investigators. A subgroup analysis of the ODYSSEY APPRISE study: Safety and efficacy of alirocumab in the Italian cohort. Nutr Metab Cardiovasc Dis. 2022 Nov;32(11):2638-2646. doi: 10.1016/j.numecd.2022.07.020. Epub 2022 Aug 9. PubMed 36064689 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2015 to primary completion in Apr 2019, 45 months.

Results were first posted in Mar 2020, 11 months after primary completion.

Of 122 industry-sponsored phase 3 interventional studies under Hypercholesterolemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 45 months is above that.

Counting every sponsor, half of 125 studies reached it within 18 months; a quarter within 10 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2015
First posted
Jun 19, 2015
StartActual
Jun 23, 2015
Primary completionActual
Apr 12, 2019
CompletionActual
Apr 12, 2019
Results first posted
Mar 30, 2020
Last update
Mar 28, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 28, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02476006
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Jun 19, 2015
Start date
Jun 23, 2015
Primary completion
Apr 12, 2019
Completion
Apr 12, 2019
Results posted
Mar 30, 2020
Last update
Mar 28, 2022

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alirocumab

Start the discussion